Hot Pharma Stocks / Ideen / Blockbuster

    Hot Pharma Stocks / Ideen / Blockbuster

    ne cxm nicht dabei gewesen.


    ---

    CYCC


    PRESS RELEASE

    Oct. 13, 2011, 7:00 a.m. EDT

    Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine

    Lead-in Portion of the Phase 3 Study Meets Prespecified Criteria Agreed in a SPA With FDA

    ANDS

    Zürich (awp) - Der Pharmagigant Roche wird die amerikanische Anadys Pharmaceuticals für rund 230 Mio USD übernehmen. Die beiden Unternehmen hätten eine Vereinbarung über den Zusammenschluss getroffen, wonach Roche Anadys im Rahmen einer Bartransaktion für 3,70 USD je Aktien vollständig übernehme, heisst es in einer Mitteilung am Montag




    http://www.google.com/finance?q=NASDAQ:ANDS#


    Pre-market: 3.58 +2.54 (244.23%)

    Re: ANDS

    Leonator wrote:

    Quote
    Zürich (awp) - Der Pharmagigant Roche wird die amerikanische Anadys Pharmaceuticals für rund 230 Mio USD übernehmen. Die beiden Unternehmen hätten eine Vereinbarung über den Zusammenschluss getroffen, wonach Roche Anadys im Rahmen einer Bartransaktion für 3,70 USD je Aktien vollständig übernehme, heisst es in einer Mitteilung am Montag



    http://www.google.com/finance?q=NASDAQ:ANDS#


    Pre-market: 3.58 +2.54 (244.23%)


    nice, haste abgeräumt?

    HALO 7.30$

    Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial


    Quote:


    http://prn.to/qO6SwC


    Halozyme Therapeutics (NASDAQ:HALO): JMP Securities upgraded its rating on this company from Mkt Perform to Mkt Outperform and changed its price target to $9.

    Hot Pharma Stocks / Ideen / Blockbuster

    HOTZENPLOTZ wrote:

    Quote
    Radient Pharmaceuticals Corporation (Public, PINK:RXPC) :)


    Hotzi ist wieder daaaaaaaa! Lange Zeit nix mehr von dir gehört, warst wohl wieder auf der Flucht vorm Kasperl und Seppel, häh??!! :) :)


    ____________________________________________


    HALO 7.55$, hab vermutet, dass da noch was geht.




    gruuuueeeess

    Hot Pharma Stocks / Ideen / Blockbuster

    vagnum wrote:


    Hey Hallo! Freut mich! Hatte es mal mit Arbeit probiert... haha! Wenn ich jetzt nicht gleich alles verzock, werd ich die kalten Winterabende über wieder hier sein und mit meinen drei Lieblingen spielen, die ich das ganze Jahr über im Auge behielt (KERX, CLDX und das nun zu den Pennystocks verdammte RXPC). Wie läufts mit den Ziggis? Liebe Grüsse. Hotzi


    PS. Sorry für OT :)

    HALO 8.15$

    Halozyme Announces Positive Results From Phase 2 Ultrafast Insulin Trials in Patients with Type 1 and Type 2 Diabetes


    Quote:

    Quote
    AN DIEGO, Oct. 21, 2011 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. HALO +5.44% , a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced positive results from two Phase 2 clinical trials of its ultrafast PH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to the insulin analog comparator, with superior reductions in post-prandial glucose excursions in the PH20 insulin analog arms. Compared to insulin analog alone, PH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets in both Type 1 and Type 2 patients. Across all of the treatment groups, there was no meaningful difference in hypoglycemia incidence or event rates. Hypoglycemia events were generally mild, and adverse events with PH20 insulin analog formulations were similar to those observed during the insulin analog comparator phase.


    http://bit.ly/r5W23b

    ARWR

    We are offering 1,000,000 shares of our Common Stock in this offering at a public offering price of $0.40 per share. This is a best efforts offering being made directly by Arrowhead, without an underwriter or placement agent. We are not required to sell any specific number or dollar amount of securities in this offering, but will use our best efforts to sell the securities offered. We will receive all of the proceeds from any securities sold in this offering. If we sell the maximum number of shares offered by this prospectus supplement, the total gross offering proceeds to us, before offering expenses, will be approximately $400,000. This offering will continue until the earlier of the sale of all shares offered by this prospectus supplement or October 31, 2011.

    Our Common Stock is quoted on The NASDAQ Capital Market under the symbol “ARWR.” On October 21, 2011, the last reported sales price of our Common Stock on The NASDAQ Capital Market was $0.46 per share.


    http://ih.advfn.com/p.php?pid=nmona&article=49672181

    ALXA 1.37$

    Alexza Pharmaceuticals Announces Submission of European Marketing Authorization Application for Adas


    Quote:


    http://bit.ly/sYx57x